452 related articles for article (PubMed ID: 8567774)
41. Hormonal treatment for bleeding irregularities in Norplant implant users.
Alvarez-Sanchez F; Brache V; Thevenin F; Cochon L; Faundes A
Am J Obstet Gynecol; 1996 Mar; 174(3):919-22. PubMed ID: 8633669
[TBL] [Abstract][Full Text] [Related]
42. The interaction between sex hormone binding globulin and levonorgestrel released from Norplant, an implantable contraceptive.
Affandi B; Cekan SZ; Boonkasemsanti W; Samil RS; Diczfalusy E
Contraception; 1987 Feb; 35(2):135-45. PubMed ID: 3109803
[TBL] [Abstract][Full Text] [Related]
43. Pregnancy after removal of Norplant implants contraceptive.
Affandi B; Santoso SS; Djajadilaga ; Hadisaputra W; Moeloek FA; Prihartono J; Lubis F; Samil RS
Contraception; 1987 Aug; 36(2):203-9. PubMed ID: 3123134
[TBL] [Abstract][Full Text] [Related]
44. Changes in vascular basement membrane in the endometrium of Norplant users.
Hickey M; Simbar M; Markham R; Young L; Manconi F; Russell P; Fraser IS
Hum Reprod; 1999 Mar; 14(3):716-21. PubMed ID: 10221702
[TBL] [Abstract][Full Text] [Related]
45. Plasma levels of levonorgestrel and free levonorgestrel index in women using NORPLANT implants or two covered rods (NORPLANT-2).
Olsson SE; Odlind V; Johansson ED; Nordström ML
Contraception; 1987 Mar; 35(3):215-28. PubMed ID: 3111784
[TBL] [Abstract][Full Text] [Related]
46. Norplant-2 subdermal contraceptive system: experience in Taiwan.
Lee TY; Yang YS; Tseng LH; Ko TM; Hsu MC; Chuang SM
J Formos Med Assoc; 1993 May; 92(5):446-50. PubMed ID: 8104598
[TBL] [Abstract][Full Text] [Related]
47. Characteristics and experiences of American women electing for early removal of contraceptive implants.
Frank ML; Ditmore JR; Ilegbodu AE; Bateman L; Poindexter AN
Contraception; 1995 Sep; 52(3):159-65. PubMed ID: 7587187
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.
Landgren BM; Johannisson E; Masironi B; Diczfalusy E
Contraception; 1982 Dec; 26(6):567-85. PubMed ID: 6820337
[TBL] [Abstract][Full Text] [Related]
49. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
[TBL] [Abstract][Full Text] [Related]
50. Experience with side effects and health risks associated with Norplant implant use in adolescents.
Rosenthal SL; Biro FM; Kollar LM; Hillard PJ; Rauh JL
Contraception; 1995 Nov; 52(5):283-5. PubMed ID: 8585884
[TBL] [Abstract][Full Text] [Related]
51. Subjective perception of bleeding and serum ferritin concentration in long-term users of Norplant.
Faundes A; Tejada AS; Brache V; Alvarez F
Contraception; 1987 Feb; 35(2):189-96. PubMed ID: 3109804
[TBL] [Abstract][Full Text] [Related]
52. A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK.
Mascarenhas L; van Beek A; Bennink HC; Newton J
Hum Reprod; 1998 Nov; 13(11):3057-60. PubMed ID: 9853856
[TBL] [Abstract][Full Text] [Related]
53. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation.
Said S; Sadek W; Rocca M; Koetsawang S; Kirwat O; Piya-Anant M; Dusitsin N; Sethavanich S; Affandi B; Hadisaputra W; Kazi A; Ramos RM; d'Arcangues C; Belsey EM; Noonan E; Olayinka I; Pinol A
Hum Reprod; 1996 Oct; 11 Suppl 2():1-13. PubMed ID: 8982739
[TBL] [Abstract][Full Text] [Related]
54. Assessing the acceptability of Norplant contraceptive in four patient populations.
Dugoff L; Jones OW; Allen-Davis J; Hurst BS; Schlaff WD
Contraception; 1995 Jul; 52(1):45-9. PubMed ID: 8521714
[TBL] [Abstract][Full Text] [Related]
55. Sex hormone binding globulin and free levonorgestrel index in the first week after insertion of Norplant implants.
Alvarez F; Brache V; Tejada AS; Cochon L; Faundes A
Contraception; 1998 Oct; 58(4):211-4. PubMed ID: 9866001
[TBL] [Abstract][Full Text] [Related]
56. Oxidative stress, vitamin E and progestin breakthrough bleeding.
Subakir SB; Abdul Madjid O; Sabariah S; Affandi B
Hum Reprod; 2000 Aug; 15 Suppl 3():18-23. PubMed ID: 11041217
[TBL] [Abstract][Full Text] [Related]
57. NORPLANT contraceptive implants advancing.
Segal SJ
Netw Res Triangle Park N C; 1984; 5(3):1-3. PubMed ID: 12279797
[TBL] [Abstract][Full Text] [Related]
58. Endometrial effects of levonorgestrel and estradiol: A Scanning electron microscopic study of the luminal epithelium.
Nilsson O; Englund D; Weiner E; Victor A
Contraception; 1980 Jul; 22(1):71-83. PubMed ID: 6774851
[TBL] [Abstract][Full Text] [Related]
59. The measurement of endometrial perfusion in norplant users: a pilot study.
Hickey M; Carati C; Manconi F; Gannon BJ; Dwarte D; Fraser IS
Hum Reprod; 2000 May; 15(5):1086-91. PubMed ID: 10783358
[TBL] [Abstract][Full Text] [Related]
60. Preliminary experience with Norplant in an inner city population.
Cullins VE; Blumenthal PD; Remsburg RE; Huggins GR
Contraception; 1993 Feb; 47(2):193-203. PubMed ID: 8449019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
